SLNK
Selank
A synthetic heptapeptide: the tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the C-terminus with Pro-Gly-Pro — the same stabilising extension used in semax, on a different parent sequence. Tuftsin is a fragment of the immunoglobulin G heavy chain. No receptor target for selank has been established in the published literature.
No registered human study names Selank as an intervention. ClinicalTrials.gov holds no trial of it, so there is no trial evidence to read — a fact about the public record rather than proof the compound does nothing. No FDA-approved product contains Selank. 19 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Selank; the registry search is fuzzy, so every match is re-checked. None of this says whether Selank works or is safe.
FDA status
Research only
Human studies
0
Furthest phase
—
Papers, 10 yr
19
Readership
6,791
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
No registered human study
0
Registered human studies
None
No FDA-approved product contains it
2 loose registry matches were checked and 0 confirmed — 2 named something else and were discarded. We count a study only when Selank is named as an intervention in it.
No study of Selank in humans is registered on ClinicalTrials.gov. That is a fact about the public record, not a statement that the compound does nothing — but it does mean there is no trial evidence to read, and anyone telling you otherwise should be asked for the registration number. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Selank is, and what it has been studied for
Selank is tracked here. Its FDA substance identifier is TS9JR8EP1G.
No registered trial names Selank as an intervention, so there is no condition it has been formally studied in. It does have a literature: 19 indexed papers name it in the last ten years. That work is laboratory and animal research, and a paper is not a trial.
Is anyone studying Selank?
Papers published each year that name Selank in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 8 | 0 | Yes |
| 2018 | 1 | 0 | Yes |
| 2019 | 3 | 0 | Yes |
| 2020 | 3 | 0 | Yes |
| 2021 | 2 | 0 | Yes |
| 2022 | 1 | 0 | Yes |
| 2023 | 0 | 0 | Yes |
| 2024 | 0 | 0 | Yes |
| 2025 | 0 | 0 | Yes |
| 2026 | 1 | 0 | No |
19 papers between 2017 and 2026. A paper counts when “Selank” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Selank
19 indexed papers name Selank in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Functional Connectomic Approach to Studying Selank and Semax Effects
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats
- Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress
- Tuftsin - Properties and Analogs
- Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission
- The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress
- GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells
Collected 2026-08-02from PubMed, phrase-matched on “Selank” in title and abstract. Run the same search.
About Selank
A synthetic heptapeptide: the tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the C-terminus with Pro-Gly-Pro — the same stabilising extension used in semax, on a different parent sequence. Tuftsin is a fragment of the immunoglobulin G heavy chain. No receptor target for selank has been established in the published literature.
- Also known as
- TP-7
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.